<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Advanced Biomed Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/advanced-biomed-inc-common-stock</link>
<description>Latest news and press releases for Advanced Biomed Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 18 Feb 2026 05:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/advanced-biomed-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683542c378dffbe2df0e16f8.webp</url>
<title>Advanced Biomed Inc. Common Stock</title>
<link>https://6ix.com/company/advanced-biomed-inc-common-stock</link>
</image>
<item>
<title>Advanced Biomed Inc. Announces 1 for 20 Share Consolidation</title>
<link>https://6ix.com/company/advanced-biomed-inc-common-stock/news/advanced-biomed-inc-announces-1-for-20-share-consolidation</link>
<guid isPermaLink="true">https://6ix.com/company/advanced-biomed-inc-common-stock/news/advanced-biomed-inc-announces-1-for-20-share-consolidation</guid>
<pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
<description>Tainan City, Taiwan, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company” or “Advanced Biomed”), a biotechnology company</description>
</item>
<item>
<title>Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery</title>
<link>https://6ix.com/company/advanced-biomed-inc-common-stock/news/advanced-biomed-inc-announces-120-130000187</link>
<guid isPermaLink="true">https://6ix.com/company/advanced-biomed-inc-common-stock/news/advanced-biomed-inc-announces-120-130000187</guid>
<pubDate>Fri, 13 Feb 2026 13:00:00 GMT</pubDate>
<description>Tainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the Company has entered into a clinical research collaboration agreement (the “Agreement”) with Chi‑Mei Medical Center to initiate a 120‑case feasibility study designed to evaluate the predictive accuracy of the Comp</description>
</item>
<item>
<title>Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary</title>
<link>https://6ix.com/company/advanced-biomed-inc-common-stock/news/advanced-biomed-inc-announces-disposal-151700367</link>
<guid isPermaLink="true">https://6ix.com/company/advanced-biomed-inc-common-stock/news/advanced-biomed-inc-announces-disposal-151700367</guid>
<pubDate>Tue, 30 Dec 2025 15:17:00 GMT</pubDate>
<description>Tainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced that on December 23, 2025, it entered into an agreement (the “Agreement”) with an unrelated third party, Wei Ha Hui (the “Buyer”), pursuant to which the Company agreed to sell 100% of the issued and outstanding</description>
</item>
<item>
<title>Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary </title>
<link>https://6ix.com/company/advanced-biomed-inc-common-stock/news/advanced-biomed-inc-announces-disposal-of-its-hong-kong-subsidiary</link>
<guid isPermaLink="true">https://6ix.com/company/advanced-biomed-inc-common-stock/news/advanced-biomed-inc-announces-disposal-of-its-hong-kong-subsidiary</guid>
<pubDate>Tue, 30 Dec 2025 05:00:00 GMT</pubDate>
<description>Tainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused</description>
</item>
<item>
<title>Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery</title>
<link>https://6ix.com/company/advanced-biomed-inc-common-stock/news/advanced-biomed-inc-announces-launch-123000091</link>
<guid isPermaLink="true">https://6ix.com/company/advanced-biomed-inc-common-stock/news/advanced-biomed-inc-announces-launch-123000091</guid>
<pubDate>Fri, 19 Sep 2025 12:30:00 GMT</pubDate>
<description>[Tainan City], Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the launch of its A+PerfusC™ system, a compact, all‑in‑one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro. (A+PerfusC™ 3D System-a perfusion-based 3D cell cu</description>
</item>
<item>
<title>Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering</title>
<link>https://6ix.com/company/advanced-biomed-inc-common-stock/news/advanced-biomed-inc-announces-closing-172900681</link>
<guid isPermaLink="true">https://6ix.com/company/advanced-biomed-inc-common-stock/news/advanced-biomed-inc-announces-closing-172900681</guid>
<pubDate>Fri, 07 Mar 2025 17:29:00 GMT</pubDate>
<description>Tainan, Taiwan, March 07, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the "Company") (NASDAQ: ADVB), a biotechnology company focused on early screening and detection, diagnosis and staging, and treatment of cancer, today announced the closing of its initial public offering (the "Offering") of 1,640,000 shares of common stock (the “Shares”), at a public offering price of $4.00 per share for total gross proceeds of $6.56 million before deducting underwriting discounts and offering expenses. The</description>
</item>
<item>
<title>Advanced Biomed Inc. Announces Pricing of Initial Public Offering</title>
<link>https://6ix.com/company/advanced-biomed-inc-common-stock/news/advanced-biomed-inc-announces-pricing-140200170</link>
<guid isPermaLink="true">https://6ix.com/company/advanced-biomed-inc-common-stock/news/advanced-biomed-inc-announces-pricing-140200170</guid>
<pubDate>Thu, 06 Mar 2025 14:02:00 GMT</pubDate>
<description>Tainan, Taiwan, March 06, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the “Company” or “Advanced Biomed”), a biotechnology company focused on early screening and detection, diagnosis and staging, and treatment of cancer, today announced the pricing of its initial public offering (the “Offering”) of 1,640,000 shares of common stock (“Common Stock”) at a public offering price of $4.00 per share. The shares of Common Stock have been approved for listing on the Nasdaq Capital Market and are expec</description>
</item>
</channel>
</rss>